Hello everyone, I’m relatively new here. I will start radiation therapy for my triple positive BC. I’m wondering if the HBOT sessions are allowed during the treatment. Impossible to get medical high pressure sessions in France but there are private centres with pressure going up to 1,5.

To every one of you walking this path — whether you’re fighting, supporting someone you love, researching late at night, or simply trying to hold things together — I want you to know how deeply respected you are. This journey is not easy. It takes courage, resilience, curiosity, and heart. And yet, despite everything, this community continues to show up with generosity, wisdom, and care for one another. That matters more than words can express. Christmas can bring joy, but it can also bring reflection, uncertainty, and mixed emotions — and all of that is okay. Wherever you find yourself today, please know you’re not alone. Wishing you peace, moments of warmth, and renewed hope as we move toward a new year together 💚

I got this very interesting article from a researcher I trust. It really helped me understand the "Que pasa" better, what's happening right now. I thought I'd share this in the hope that it might help with your search in making an informed decision. Enjoy reading ------------------------------- Cancer Treatment Is Not a Drug Problem It Is an Engineering Problem We Have Systematically Avoided. Preface: How the cancer treatment market is currently structured. Before discussing why cancer treatment remains so ineffective, it is necessary to understand where global resources are actually going. Based on public health expenditure data and industry reports, the global cancer treatment market can be broadly divided into three components: 1. Cancer drugs (chemotherapy, targeted therapy, immunotherapy) 2. Medical services (hospitalization, surgery, imaging, monitoring, follow-up care) 3. Therapeutic medical devices (interventional, ablative, physically acting systems) A conservative, order-of-magnitude estimate suggests: 1. Cancer drugs: approximately USD 200–250 billion per year 2. Cancer-related medical services: approximately USD 400–600 billion per year 3. Therapeutic medical devices: likely below USD 100 billion per year In other words: More than 80–90% of global cancer spending is currently absorbed by drugs and services, while engineering-based therapeutic devices account for only a small fraction of total value. This distribution is not driven by outcomes. It is driven by how cancer has been defined as a problem. 1. The paradox of massive investment and persistent failure Every year, over 10 million people die from cancer worldwide. These deaths are often explained away as consequences of: Late diagnosis Unequal access Insufficient funding Limited technology Yet this explanation collapses under closer inspection. A large proportion of cancer patients today: Receive multiple lines of treatment Are treated in well-funded healthcare systems

Welcome Warrior. Share as much or as little as you feel comfortable — your diagnosis or loved one’s journey, your goals, questions, therapies you’re exploring, or even a photo to help us connect a face to the story. (Post Category: 👋 Introductions) Every share helps others feel less alone and keeps the community growing stronger. Please comment below to acknowledge that you’ve read our community guidelines: 📏 Demonstrate mutual respect and unconditional positive regard 📏 Assume positive intentions 📏 Ground statements in evidence 📏 Share lived experience — but do not give medical advice 📏 Do not use this group for personal financial gain — our mission is to help more Warriors ✅ Explore the Classroom Start here to get grounded and make the most of your time: ✅ Stay Active to Support Our Mission Skool ranks communities by engagement (posts, comments, likes, member activity). The more we interact, the more people discover us — and the more lives we can potentially impact. Download the app on your phone to stay connected. Thank you for being here, for contributing, and for fighting this battle together. 💙 ⚠️ Important Notice: The information provided here is for educational purposes only and is not medical advice. Disclaimer: Neither this community nor its administrators assume responsibility for how this information is used. All medical decisions, including whether to start or stop any medication, must be made with the guidance of a qualified healthcare provider.

Hey Warriors 🙂, I’ve been a bit quieter lately as we’ve been working behind the scenes on something important: My mum completed the Astron Health multi-omic analysis, and the results have finally arrived. Next week we meet Astron’s integrative oncologist to go through the full interpretation — but I want to share the key insights now, because this is something that can empower every person in this community. ⭐ What Astron Revealed About My Mum’s Cancer Her tumour is not random. It runs on specific biological pathways — almost like an engine with identifiable components. The major drivers they identified were: 🔥 FGFR2 → MAPK (Main Growth Engine) 🔥 VEGF / Angiogenesis (Blood Supply) 🔥 MMP15 (Invasion + Tissue Breakdown) 🔥 WNT Signalling (Stem-Cell Survival + Recurrence) 🔥 FANCA Mutation (DNA-Repair Weakness → ROS Sensitivity) And important update: ➡️ CTCs were only 2, which is very low and extremely reassuring. ⭐ This Report Was NOT Essential — But It Was Incredibly Helpful I want to make something clear to everyone: You do NOT need expensive molecular testing to build an effective, multi-pathway protocol. Over the past 1.5 years, I created my mum’s protocol by studying: - cancer signalling pathways - metabolic vulnerabilities - invasion markers - angiogenesis mechanisms - mitochondrial weaknesses - stem-cell biology And what shocked me was this: The Astron findings matched almost exactly what I had already built through research alone. This is HUGE for this community. It proves that: ✔ you can learn what drives your cancer ✔ you can build precision strategies without testing ✔ you can target the actual pathways behind the disease ✔ you do NOT need to shoot in the dark The report confirmed the work — it didn’t create it. ⭐ The One Pathway We Had Not Fully Targeted: RAS → MAPK Astron’s report highlighted one important component: Atorvastatin This inhibits RAS prenylation, which is the top upstream switch that activates the MAPK pathway — the main engine of her tumour.